BTK Inhibition (Tolebrutinib HERCULES Phase 3) Delays Disability Progression in Non-Relapsing Secondary Progressive Multiple Sclerosis with Liver-Safety Monitoring Requirement

Tolebrutinib, a Bruton tyrosine kinase inhibitor designed to enter the brain, met its primary endpoint in a Phase 3 trial in non-relapsing secondary progressive multiple sclerosis, with a liver-safety monitoring requirement.

Type

evidence-claim

Domain

h11_chronic_inflammation

Grade

A

License

CC BY-NC 4.0

card_id

L-022

hallmarks

h11_chronic_inflammation,h10_altered_intercellular_communication

cluster

clinical_translation

primary_disease_area

longevity_general

evidence_tier

A

evidence_anchor_count

4

intake_round

R23

intake_date

2026-05-26

related_experts

related_biomarkers

related_interventions

related_trials

NCT04410991

collection_pages

/research/interventions/btk-inhibitors,/research/trials/hercules-spms

LongProof Longevity Dynamic · LIGHT HOPE / x1000.ai · longevity.x1000.ai · 2026 · source

Read-only aggregated view. Longevity Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.